Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Acorda Therapeutics, Inc. - Common Stock (NQ: ACOR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acorda Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Acorda Therapeutics Announces Delisting from Nasdaq
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Nasdaq Delisting Notification
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
From Acorda Therapeutics
Via Business Wire
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
From Acorda Therapeutics Acorda Therapeutics, Inc.
Via Business Wire
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Inc. (NASDAQ: ACOR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
From Acorda Therapeutics
Via Business Wire
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
From Acorda Therapeutics
Via Business Wire
Tom Burns Elected to the Acorda Therapeutics Board of Directors
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports First Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
From Acorda Therapeutics
Via Business Wire
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
From Acorda Therapeutics
Via Business Wire
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
ESTEVE Launches INBRIJA® in Spain
From Acorda Therapeutics
Via Business Wire
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
From Acorda Therapeutics
Via Business Wire
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.